AUA 2020: Inherited Cancer Predisposition Gene Variants in Patients with Non-Muscle Invasive Bladder Cancer

(UroToday.com) The genetic landscape of bladder cancer has been generally poorly examined, compared for example with prostate cancer. However, there are intriguing emerging data that suggest that many patients with locally advanced and metastatic urothelial cancer harbor rare germline variants in cancer predisposition genes, including in DNA damage response (DDR) genes. This, however, has not been […]

AUA 2020: Pivotal Trial of MRI-Guided Transurethral Ultrasound Ablation in Men with Localized Prostate Cancer: Two-Year Follow-Up

(UroToday.com) Prostate cancer is the most common non-cutaneous malignancy among men in the western world, with the vast majority of men having clinically localized disease at the time of diagnosis. For patients with low-risk disease, active surveillance is widely accepted. For patients opting for active treatment, currently accepted treatments including radical prostatectomy and radiotherapy provide […]

AUA 2020: Decision-Analytic Modeling Study of the PRECISION Trial: Does Pre-Biopsy MRI Do More Good Than Harm?

(UroToday.com) The utilization of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and management of prostate cancer has rapidly expanded in the past few years. The recent PRECISION trial, along with others, have examined the value of mpMRI prior to prostate biopsy in men with elevated PSA levels. In general, these studies have demonstrated a […]

AUA 2020: Impact of Baseline Disease Volume and Prior Docetaxel Therapy On Prostate-Specific Antigen-Related Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide plus Androgen Deprivation Therapy

(UroToday.com) Enzalutamide is an approved drug in the United States for the treatment of metastatic hormone-sensitive prostate cancer based on the phase three ARCHES study (NCT02677896)1 and supported by the phase 3 ENZAMET trial (NCT02446405).2 Both these trials demonstrated improved clinical outcomes, including radiographic progression-free survival and overall survival with enzalutamide versus the comparator arm. 

AUA 2020: Surrogate Endpoints for Overall Survival for Patients with Metastatic Hormone-Sensitive Prostate Cancer in the CHAARTED Trial

(UroToday.com) Prostate cancer is the most commonly diagnosed male malignancy, developing in one out of nine men during their lifetime. Metastasis free survival has been shown to be a robust surrogate for overall survival in men with non-metastatic prostate cancer. However, this surrogate only holds true for a select subset of patients and leaves those trials […]

AUA 2020: Prostate Mapping for Cancer Diagnosis: The Madrid Protocol — Transperineal Prostate Biopsies Combining Micro-Ultrasound and mpMRI Fusion Biopsy

(UroToday.com) There has been rapid uptake in the use of multi-parametric magnetic resonance imaging (mpMRI) in the evaluation and diagnosis of patients at risk for prostate cancer. It is widely felt to be a useful tool that decreases rates of diagnosis of low-risk disease while increasing rates of diagnosis of clinically significant disease. However, it […]

AUA 2020: Cost-Effectiveness of Maintenance BCG for Intermediate and High Risk Non-Muscle Invasive Bladder Cancer

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. BCG is administered with both induction and maintenance phases.

AUA 2020: Is Radiotherapy the Devil’s Work?

(UroToday.com) In a plenary session at the American Urologic Association Virtual Annual Meeting, Kenneth Angermeier, MD, FACS moderated a session titled: “Is Radiotherapy the Devil’s Work?” Along with panelists Tamsin Greenwell, MD, Sean Elliott, MD, MS, and Francisco Martins, MD, Dr. Angermeier walked through a discussion of this premise. To begin, Dr. Angermeier highlighted that […]

X